SCHEMBL23218296

SCHEMBL23218296

CCOC(=O)Cc1ccccc1OCc1coc2c(N(C)C)cc(Cl)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.37
NPC1 O15118 1/20 0.36
CFD P00746 1/20 0.36
MAPT P10636 3/20 0.35
TP53 P04637 1/20 0.35
THRB P10828 1/20 0.35
PKM P14618 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
NPSR1 Q6W5P4 1/20 0.33
SLC1A5 Q15758 1/20 0.33
DHFR P00374 1/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
PAX8 Q06710 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852866 1.00 TBXAS1 (0.39) TBXAS1PTGDR2NPC1CFDMAPT
SCHEMBL23219098 0.87 TBXAS1 (0.40) TBXAS1PTGDR2NPC1CFDMAPT
SCHEMBL29591267 0.87 TBXAS1 (0.40) TBXAS1PTGDR2NPC1CFDMAPT
SCHEMBL29591201 0.85 MAPT (0.39) TBXAS1PTGDR2NPC1CFDMAPT
SCHEMBL23218319 0.85 MAPT (0.39) TBXAS1PTGDR2NPC1CFDMAPT
SCHEMBL29853027 0.85 MAPT (0.39) TBXAS1PTGDR2NPC1CFDMAPT
SCHEMBL23218123 0.84 MAPT (0.38) TBXAS1PTGDR2NPC1CFDMAPT
SCHEMBL29853049 0.84 MAPT (0.38) TBXAS1PTGDR2NPC1CFDMAPT
SCHEMBL29591621 0.84 MAPT (0.38) TBXAS1PTGDR2NPC1CFDMAPT
SCHEMBL23218713 0.83 PTGDR2 (0.39) TBXAS1PTGDR2NPC1CFDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TBXAS1 963/4885PTGDR2 484/4885NPC1 324/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TBXAS1 392/4885PTGDR2 976/4885NPC1 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.